Ownership and insider activity for Janux Therapeutics, Inc. (JANX): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors.
Price
| Price | $16.25 |
| Market Cap | $991M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-07-31 | Campbell David Alan | G-Gift | 123,840 | |
| 2026-07-08 | Campbell David Alan | M-Exempt | 7,000 | $29K |
| 2026-07-08 | Campbell David Alan | M-Exempt | 7,000 | $29K |
| 2026-06-11 | RA CAPITAL MANAGEMENT, L.P. | A-Award | 15,500 | $212K |
| 2026-06-11 | RA CAPITAL MANAGEMENT, L.P. | A-Award | 5,500 | |
| 2026-06-11 | Simson Jake | A-Award | 15,500 | $212K |
| 2026-06-11 | Simson Jake | A-Award | 5,500 | |
| 2026-06-11 | Kung Winston | A-Award | 15,500 | $212K |
| 2026-06-11 | Kung Winston | A-Award | 5,500 | |
| 2026-06-11 | Hernday Natasha | A-Award | 15,500 | $212K |
Balance Sheet (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $658000 | $7.8M | $35.6M | $51.4M | $19.2M | $430.6M | $52.3M |
| Short-term Investments | 0 | 0 | $339.4M | $275.6M | $324.8M | $594.6M | $914.2M |
| Receivables | 0 | $8.0M | $200000 | $700000 | $2.2M | $5.4M | $6.4M |
| Inventory | 0 | 0 | 0 | -$700000 | 0 | 0 | 0 |
| Total Current Assets | $658000 | $16.1M | $377.0M | $332.4M | $349.2M | $1.03B | $975.9M |
| Property, Plant & Equipment | $21000 | $155000 | $1.6M | $29.4M | $27.8M | $24.1M | $22.3M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $679000 | $16.2M | $379.8M | $364.0M | $380.4M | $1.06B | $1.01B |
| Accounts Payable | $267000 | $428000 | $2.5M | $2.2M | $2.4M | $4.0M | $5.0M |
| Short-term Debt | $4.0M | 0 | 0 | 0 | 0 | 0 | $2.4M |
| Total Current Liabilities | $4.6M | $3.2M | $12.8M | $16.5M | $13.0M | $17.5M | $25.0M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $8.6M | $30.9M | $13.5M | $43.3M | $36.1M | $38.7M | $50.7M |
| Retained Earnings | -$8.0M | -$14.7M | -$47.4M | -$110.5M | -$168.8M | -$237.8M | -$351.4M |
| Total Equity | -$7.9M | -$14.6M | $366.3M | $320.7M | $344.3M | $1.02B | $956.8M |
| Total Debt | $4.0M | 0 | $194000 | $25.3M | $24.5M | $23.0M | $22.1M |
| Net Debt | $3.3M | -$7.8M | -$374.8M | -$301.7M | -$319.5M | -$1.00B | -$944.4M |
| Working Capital | -$4.0M | $12.9M | $364.2M | $315.9M | $336.2M | $1.02B | $950.9M |
Financial Health
| Debt / Equity | 0.02 |
| Current Ratio | 16.35 |
Profitability
| Return on Equity | -10.79% |
| Return on Invested Capital | -15.11% |
| Return on Assets | -10.18% |
| Gross Margin | 68.91% |
| Operating Margin | -450.30% |
| Net Margin | -321.81% |
Related companies: ABCL · BHVN · CLDX · HRMY · IMNM · MAZE · NUVB
Explore sector: Healthcare · Biotechnology
More sections of JANX: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks